Molecular Tuning of a Vitamin E-Scaffold PH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic SiRNA Delivery
Overview
Biotechnology
Authors
Affiliations
A lipid nanoparticle (LNP) composed of a series of SS-cleavable and pH-activated lipid-like materials (ssPalm) was previously developed as a platform of a gene delivery system. A tertiary amine and disulfide bonding were employed to destabilize the endosomal membrane and for intracellular collapse. We report herein on the development of a hepatocyte-targeting siRNA carrier by the molecular tuning of the hydrophobic scaffold, and tertiary amine structures. The gene knockdown activity against a hepatocyte-specific marker (factor VII: FVII) was improved when a more fat-soluble vitamin (vitamin E) was employed as a hydrophobic scaffold. Moreover, to allow the tertiary amines to accept protons by sensing a slight change in endosomal acidification, its structural flexibility was minimized by fixing it in a piperidine structure, and the distance between the surface of the particle to the ternary amine was increased. As a result, the p value was increased to the approximately 6.18 depending on its distance, while the p reached plateau when the tertiary amine was linked by an excess number of linear carbon chains. The pH-dependent membrane destabilization activity, as assessed by a hemolysis assay, was increased in parallel with the p value. Moreover, the gene knockdown activity was improved in parallel with hemolytic activity. Finally, further optimization of the lipid/siRNA ratio, and the use of chemically (2'-fluoro) modified siRNA synergistically improved the gene knockdown efficacy to an effective dose (ED) of 0.035 mg/kg. The developed ssPalm represents a promising platform for use as a hepatocyte-targeting siRNA carrier.
A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.
Sawamura M, Tachikawa K, Hikawa R, Akiyama H, Kaji S, Yasuda K Mol Ther Nucleic Acids. 2024; 35(4):102380.
PMID: 39640012 PMC: 11617236. DOI: 10.1016/j.omtn.2024.102380.
Oyama R, Ishigame H, Tanaka H, Tateshita N, Itazawa M, Imai R ACS Nano. 2023; 17(19):18758-18774.
PMID: 37814788 PMC: 10569098. DOI: 10.1021/acsnano.3c02251.
A Lipid Nanoparticle-Based Method for the Generation of Liver-Specific Knockout Mice.
Morita S, Horii T, Kimura M, Kobayashi R, Tanaka H, Akita H Int J Mol Sci. 2023; 24(18).
PMID: 37762602 PMC: 10532048. DOI: 10.3390/ijms241814299.
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases.
Kalita T, Abbasi Dezfouli S, Pandey L, Uludag H Pharmaceutics. 2022; 14(11).
PMID: 36432711 PMC: 9694336. DOI: 10.3390/pharmaceutics14112520.
Sakurai Y, Watanabe H, Nishio K, Hashimoto K, Harada A, Gomi M Pharmaceutics. 2022; 14(8).
PMID: 36015185 PMC: 9413996. DOI: 10.3390/pharmaceutics14081560.